A leader in allergen immunotherapy
With more than a century of expertise in allergies and allergen immunotherapy (AIT), Stallergenes Greer is a leader in its field.
Stallergenes Greer, a fully integrated global biopharmaceutical company, specialises in the diagnosis and treatment of allergies through the research, development and commercialisation of AIT products and services for respiratory and food allergies.
The company’s product portfolio, which covers a broad range of administration modes (subcutaneous, sublingual drops and tablets for respiratory allergies, and powder to be consumed with semi-solid foods for peanut allergies), offers healthcare professionals innovative, safe and effective solutions to improve life for people with allergies.
About allergen immunotherapy
Allergen immunotherapy (AIT) is an allergy treatment designed to treat the underlying cause of the disease as well as have a carry-over effect on all symptoms. After an accurate diagnosis of the type of allergy and responsible allergens, patients, in line with their healthcare practitioner’s prescription, receive a targeted treatment. Through the repeated administration of specific allergens, the immune system builds resistance1 thus reducing symptoms when patients are exposed to the allergen in their environment.
A robust shareholding structure
Stallergenes Greer is a private company owned by interests associated with the Bertarelli family, which are advised by B-FLEXION.
B-FLEXION is a business enterprise for the managers and advisers of the funds and investments associated with the Bertarelli family. The group is active in two areas: life sciences and asset management. Chaired by Ernesto Bertarelli, B-FLEXION is headquartered in Geneva, with offices in London, Jersey, Boston and Luxembourg.
To learn more about Stallergenes Greer, read our 2022 Company report
1. Global Atlas of Allergy, EAACI 2014